Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

The GmNN1/FT2a-GmNFYA-C-GmENOD40 module regulates soybean nodulation. by Xinxin Li (281237)

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

“…<p>(A-B) GCase, (C-D) gluocosylceramide (GlcCer), and (E-F) glucosylsphingosine (GlcSph) levels measured in whole brain homogenate and liver homogenate of C57Bl/6 wild type (WT) and <i>GBA1</i> D409V KI heterozygous (HET) mice at 5 months of age (n = 10/age). …”

Fig 5 - by Mestewat Simeon (19233200)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

<i>C</i>. <i>auris</i> induces IL-1Ra in macrophages to decrease the neutrophil function in the skin. by Abishek Balakumar (20189865)

Geometric mean concentrations of 5 most abundant PCDD/F congeners and the sum of other congeners (A), and PCDD and PCDF TEQ (C) in different study areas during the first (1972–1986... by Matti Viluksela (321291)

Locations of projected refugia for all five taxa with 2°C and 4.5°C warming. by Rhosanna L. M. Jenkins (11167230)

Glucose-lowering efficacy. by Sungmin Kim (628527)

Subjects:

Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

Subjects: